PIK3CA and breast carcinoma: In a clinical study using 55 patients with breast cancer, Berns et al. [62] described significantly improved ability to detect patients with low response to trastuzumab when combining the analysis of low PTEN expression with the presence of oncogenic PIK3CA mutations.